"AI Reshapes Drug Development" China Targets Biotech Dominance with Government-Backed AI-Powered Personalized Cancer Vaccine Manufacturing Plant

Expansion of AI-Driven R&D Automation Ushers in the Era of Personalized Therapies
Paradigm Shift in Drug Development from Candidate Discovery to Manufacturing
Regulatory Reforms and Massive State Investment Become China's Weapons for Global Market Expansion

China is strengthening its position in the race to develop next-generation therapeutics by building artificial intelligence (AI)-powered personalized cancer vaccine manufacturing facilities. As AI reshapes the entire research and development (R&D) process—from candidate discovery and clinical development to manufacturing—China is accelerating commercialization by combining regulatory innovation with large-scale government support. Industry observers say the competition in AI is rapidly evolving into a contest between national industrial ecosystems, allowing China to narrow the gap with global leaders at an increasingly faster pace.

Likang Life Sciences Builds China's First AI Cancer Vaccine Manufacturing Plant

According to the South China Morning Post (SCMP) on June 30, Chinese biotechnology company Likang Life Sciences has begun constructing a personalized tumor vaccine manufacturing line that leverages AI technology to help address the country's millions of newly diagnosed cancer patients each year. The project carries a total investment of approximately $15.3 million, including both R&D facilities and China's first AI-powered manufacturing line dedicated to personalized tumor vaccines. The facility is scheduled to begin operations in October this year, with the primary objective of establishing a precision medicine platform spanning patient-specific cancer genome analysis, vaccine design, and manufacturing.

Likang Life Sciences' lead candidate, LK101, analyzes genetic mutations within a patient's tumor to identify individualized neoantigens before using AI algorithms to select targets most likely to trigger immune responses and produce a messenger RNA (mRNA)-based vaccine. In 2023, the company became the first in China to receive clinical trial authorization from the National Medical Products Administration (NMPA) for a personalized neoantigen mRNA cancer vaccine. Last year, it also secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), marking the first tumor neoantigen mRNA vaccine developed by a Chinese company to enter U.S. clinical trials.

The project reflects a broader global effort across the pharmaceutical and biotechnology industries to overcome the limitations of conventional drug discovery by integrating advanced software technologies. Unlike conventional vaccines, cancer vaccines cannot be mass-produced as standardized products. Because every patient's tumor genetics and immune system differ, each vaccine must be newly designed using neoantigens extracted from the individual's tumor.

AI plays a central role by analyzing massive genomic datasets to identify neoantigens with the highest likelihood of inducing immune responses and rapidly designing vaccine candidates. As a result, manufacturing processes must also operate under patient-specific, on-demand production systems, requiring facilities optimized for flexible, small-batch manufacturing rather than conventional mass production. China's decision to establish dedicated AI-powered personalized cancer vaccine production facilities reflects a strategy to embed these technological characteristics directly into its industrial infrastructure.

Financial markets have also expressed optimism. According to Bank of America's (BoA) macroeconomic analysis, the global AI-powered healthcare market is projected to reach $1 trillion in asset value by 2035. In an investment report published earlier this year, Alec Stranahan, BoA's senior biotechnology research analyst, said, "AI offers a compelling solution by automating complex workflows that previously required extensive manual effort, dramatically improving diagnostic accuracy, and enabling highly personalized treatment strategies tailored to individual patients."

Competition for AI Biotechnology Leadership Intensifies

AI's role extends far beyond personalized vaccine design. Across the global pharmaceutical and biotechnology industries, AI and automation technologies are being integrated throughout the entire drug development process. From candidate identification and preclinical research to clinical trial design and manufacturing process management, digital systems are increasingly assuming responsibilities once handled directly by researchers, fundamentally transforming R&D itself.

The most significant change is development speed. Traditional drug discovery required researchers to repeatedly synthesize and test countless candidate compounds before validating their therapeutic potential—a process characterized by enormous costs, lengthy timelines, and high failure rates. Today, AI analyzes vast volumes of life sciences data, scientific literature, and clinical results to identify the most promising candidates first while simultaneously predicting toxicity and drug responses, significantly shortening early-stage research.

Laboratory operations are also evolving. Industry experts note that automated robotics, high-throughput analytical equipment, and cloud-based data platforms are increasingly handling repetitive experiments, sample management, and data processing. This allows researchers to devote more attention to hypothesis generation, interpretation of findings, and clinical strategy development, substantially improving research efficiency.

At BIO USA, held in Boston on June 24 (local time), leading global pharmaceutical companies unveiled strategies centered on AI as core infrastructure. Companies including Insilico Medicine—which recently entered a joint AI drug discovery partnership with SK Biopharmaceuticals—Recursion, and Roche reported that several pipeline candidates have advanced from Phase II into Phase III clinical trials, raising expectations for commercialization. Global technology companies such as Google and Nvidia, along with South Korean firms including Celltrion, LG Chem, JW Pharmaceutical, and Dong-A ST, have also joined the intensifying race.

Industry experts believe AI is reducing both development costs and timelines by eliminating low-probability candidates early in the drug development process while improving the precision of clinical trial design. Moreover, as AI accelerates development cycles, the basis of competitive advantage is shifting. Whereas securing superior drug candidates was once the defining strength, success is now increasingly determined by a company's ability to integrate R&D, clinical development, and manufacturing into a seamless end-to-end ecosystem.

China's Regulatory Overhaul Accelerates AI Drug Commercialization

Against this backdrop, China appears increasingly well positioned to capture global leadership in AI-driven drug development. As Beijing designates innovative medicines as a national strategic industry, companies are encouraged to focus on R&D while the government provides regulatory support, financing, and manufacturing infrastructure. Industry analysts view this policy framework as a key force accelerating the commercialization of AI-enabled therapeutics.

China has steadily reformed its pharmaceutical regulatory framework over the past several years with a focus on innovative medicines. The NMPA recently proposed reducing the review period for Investigational New Drug applications for certain qualifying therapies to 30 business days after submission. The proposal introduces a new 30-business-day expedited pathway alongside the existing 60-business-day implied approval mechanism, enabling faster entry into clinical trials. The measure is expected to shorten time-to-market for innovative therapies while reducing corporate R&D burdens.

Government funding has also expanded aggressively. China's central and local governments continue to channel substantial investment into AI drug discovery, mRNA platforms, and cell and gene therapies through major national science and technology initiatives, industrial funds, and biotechnology cluster development programs. Combined with dedicated industrial infrastructure, these initiatives provide companies with a stronger foundation for rapidly expanding both clinical development and manufacturing capacity.

The effectiveness of this support framework is reflected in the rapid growth of China's AI drug developers. Chinese biotechnology company Insilico Medicine has expanded its clinical pipeline in both China and overseas through its generative AI-powered drug discovery platform. More recently, it reaffirmed its technological capabilities by signing an AI drug development agreement worth $2 billion with U.S. pharmaceutical giant Eli Lilly. The deal highlights the expanding collaboration between Chinese AI biotechnology firms and global pharmaceutical companies, as Chinese developers simultaneously advance candidate discovery, clinical development, and international licensing, broadening the global AI drug development ecosystem.